Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2012 | 01:16am CEST

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
10/19 NOVARTIS : Recent Findings from Novartis Provide New Insights into Glucosyltrans..
10/19 GILEAD SCIENCES : 2nd gene therapy for blood cancer approved
10/19 NOVARTIS : Drug Revolade(R) Shows Long-Term Disease Control for Chronic/Persiste..
10/19 NOVARTIS : sheds generics plant and 450 jobs amid pricing pressure
10/19 NOVARTIS : FDA OKs 2nd gene therapy for blood cancer; 1st for adults
10/18 NOVARTIS : 450 jobs to go as pricing pressures push Novartis to close CO generic..
10/18 NOVARTIS : drug Revolade® shows long-term disease control for chronic/persistent..
10/13 NOVARTIS : Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoretinal ..
10/13 NOVARTIS : 65-- Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoret..
10/13 NOVARTIS AG (ADR)(NYSE : NVS) Says It Will Not Sell Its Stake In Roche
More news
News from SeekingAlpha
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 BIOTECH FORUM DAILY DIGEST : Spotlighting Ignyta's Big Recent Rally
10/19 What 'Yes' For Its CAR-T Therapy May Mean For Gilead
10/19 YOUR DAILY PHARMA SCOOP : Gilead's Brave New World, AZN's Lynparza SNDA, RXDX En..
10/19 FDA Approval Of Gilead CAR-T Therapy Will Move The Needle
Financials ($)
Sales 2017 48 864 M
EBIT 2017 11 614 M
Net income 2017 7 295 M
Debt 2017 17 700 M
Yield 2017 3,32%
P/E ratio 2017 24,53
P/E ratio 2018 21,59
EV / Sales 2017 5,00x
EV / Sales 2018 4,78x
Capitalization 226 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 1,9%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.50%226 404
JOHNSON & JOHNSON23.60%382 202
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223
AMGEN27.41%133 501